Overview

  • Product name
  • Description
    Goat polyclonal to ProSAAS
  • Host species
    Goat
  • Tested applications
    Suitable for: IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rabbit, Guinea pig, Chimpanzee, Monkey, Gorilla
  • Immunogen

    Synthetic peptide corresponding to Human ProSAAS aa 182-193 (internal sequence) (Cysteine residue).
    Sequence:

    EAGDETPDVDPE


    Database link: Q9UHG2

  • Positive control
    • Human pancreas tissue.

Properties

Applications

Our Abpromise guarantee covers the use of ab191283 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 5 µg/ml.

Target

  • Function
    May function in the control of the neuroendocrine secretory pathway. Proposed be a specific endogenous inhibitor of PCSK1. ProSAAS and Big PEN-LEN, both containing the C-terminal inhibitory domain, but not the further processed peptides reduce PCSK1 activity in the endoplasmic reticulum and Golgi. It reduces the activity of the 84 kDa form but not the autocatalytically derived 66 kDa form of PCSK1. Subsequent processing of proSAAS may eliminate the inhibition. Slows down convertase-mediated processing of proopiomelanocortin and proenkephalin. May control the intracellular timing of PCSK1 rather than its total level of activity. The function of the processed secreted peptides is not known.
  • Tissue specificity
    Expressed in brain and pancreas.
  • Domain
    ProSAAS(1-180) increases secretion of enzymatically inactive PCSK1.
    The C-terminal inhibitory domain is involved in inhibtion of PCSK1. It corresponds to the probable processing intermediate Big PEN-LEN, binds to PCSK1 in vitro and contains the hexapeptide L-L-R-V-K-R, which, as a synthetic peptide, is sufficient for PCSK1 inhibition.
  • Post-translational
    modifications
    Proteolytically cleaved in the Golgi.
    O-glycosylated with a core 1 or possibly core 8 glycan.
  • Cellular localization
    Secreted. Golgi apparatus > trans-Golgi network. A N-terminal processed peptide, probably Big SAAS or Little SAAS, is accumulated in cytoplasmic protein tau deposits in frontotemporal dementia and parkinsonism linked to chromosome 17 (Pick disease), Alzheimer disease and amyotrophic lateral sclerosis-parkinsonism/dementia complex 1.
  • Information by UniProt
  • Database links
  • Alternative names
    • b-LEN antibody
    • b-PEN-LEN antibody
    • b-SAAS antibody
    • Big LEN antibody
    • granin like neuroendocrine peptide antibody
    • l-LEN antibody
    • l-SAAS antibody
    • N-proSAAS antibody
    • OTTHUMP00000032426 antibody
    • PCSK1_HUMAN antibody
    • Pcsk1n antibody
    • pro-SAAS antibody
    • Proprotein convertase 1 inhibitor antibody
    • Proprotein convertase subtilisin/kexin type 1 inhibitor antibody
    • PROSAAS antibody
    • SAAS antibody
    • SAAS CT(1-49) antibody
    • SAAS CT(25-40) antibody
    see all

Images

  • Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human pancreas tissue labeling ProSAAS with ab191283 at 5 µg/ml.

References

ab191283 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab191283.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up